Novavax, Inc.
https://novavax.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Novavax, Inc.
Deal Watch: Bristol Adds To Vaccines ‘Repertoire,’ Takes ‘Scenic’ View Of Cellular Pathways
BMS partners with Repertoire and Scenic, plus deals involving: G1/Pepper, Harmony/Epygenix, Biodexa/Emtora, Regeneron/Mammoth, Vertex/Treefrog and Immedica/KKR/Impilo.
Key Activist Investor Throws Shade At Novavax Over COVID-19 Vaccines
Shah Capital Management said Novavax could tap the estimated 100 million Americans uncomfortable with mRNA vaccines, such as those from Pfizer/BioNTech and Moderna.
COVID Vaccines: CDC Panel Says Older People ‘Should’ Get An Extra Dose
However, David Kaslow, director of the FDA’s vaccines office, says only a ‘may’ recommendation is supported and that giving an extra dose after June ‘may not be optimal’ if vaccines are reformulated for the fall.
Will Pfizer/BioNTech And Moderna Stay Atop The COVID-19 Vaccine Market Forever?
BIO CEO panelist Rajeev Venkayya argued that the huge amount of investment in COVID-19 vaccines makes it possible for new players to challenge Comirnaty and Spikevax’s dominance.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Vaccines
-
Biotechnology
- Liposomes
- Other Names / Subsidiaries
-
- CPL Biologicals Pvt. Ltd. (Joint Venture with Cadila)
- Isconova AB
- Novavax AB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice